• Company
• Opdivo combo in review for esophageal cancer indication
• by Eo, Yun-Ho Nov 24, 2021 05:53am

• Policy
• Discussions began on the scope of Mifegymiso license
• by Lee, Tak-Sun Nov 24, 2021 05:53am

• Product
• AstraZeneca vaccination is expected to end as of this year
• by Nov 24, 2021 05:53am

• Policy
• Betmiga PR prices fluctuated 3 times Between 15 days
• by Kim, Jung-Ju Nov 24, 2021 05:53am

• Policy
• MFDS cautious on waiving bridging trial for abortion pill
• by Choi-sun Nov 24, 2021 05:53am

• Policy
• Nam In-soon's drug price recovery bill excludes rebates
• by Lee, Jeong-Hwan Nov 23, 2021 05:55am

• Company
• Bavencio cost support provided in non-reimbursed areas
• by Eo, Yun-Ho Nov 23, 2021 05:54am

• Company
• Myungin signed an exclusive license agreement for Parkinson
• by Nov 23, 2021 05:54am

• Company
• Maven Clad can be prescribed in Big 5
• by Eo, Yun-Ho Nov 23, 2021 05:54am

• Policy
• Brilinta’s price cut 30%, Nexavar’s premium stays 1 year
• by Kim, Jung-Ju Nov 23, 2021 05:54am